Successful treatment of CARD14‐negative juvenile Pityriasis rubra pilaris with Ustekinumab

Abstract

Dear Editor, Juvenile Pityriasis rubra pilaris (PRP) is an orphan disease without established efficient treatment options. Interleukin-17 inhibitors and ustekinumab, a combined interleukin-12 and interleukin-23 inhibitor, have shown promising results in several case reports. [1][2][3] In particular, ustekinumab is emerging as a potential first-line treatment for the subgroup of patients with CARD14 variants. 4 CARD14 variants are seen as a predisposing factor to autoinflammatory keratinization, as seen in juvenile PRP. [4][5][6] Here, we report the successful treatment with ustekinumab in a juvenile PRP patient without CARD14 mutation, proposing to overthink the potential range of indication.